Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Recruitment completed in phase III FORTRESS study of balixafortide

Oct. 29, 2020

Australian regulatory authorities approve phase I study of APL-1501

Oct. 29, 2020

CDK2/cyclin E inhibitors synthesized by Incyte

Oct. 29, 2020

Aligos Therapeutics presents new PRMT5 inhibitors

Oct. 29, 2020

Drugging resistant androgen receptors

Oct. 29, 2020

Novel selective TRK degraders effectively reduce TPM3-TRKA fusion protein levels

Oct. 28, 2020

Apollomics reports phase I data for APL-101

Oct. 28, 2020

First-in-human data presented for TPX-0022

Oct. 28, 2020

SIMR-1281: a novel candidate for clinical trials in cancer

Oct. 28, 2020

XL-092: a promising pan-tyrosine kinase inhibitor in clinical development

Oct. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...